The ECE Forums, introduced at the 10th ECE in London (2012), have proven a successful, popular addition to the programme of sessions at the ECE, enabling a wider participation amongst delegates.

ECE Forums are intended to be less formal than traditional sessions, and to have a workshop flavour and be more interactive. The format of the ECE Forum is flexible – discussion, debate, workshop, data blitz, etc.

 

Biomarkers to predict the ketogenic diet and how to get started

Chair: Martha Feucht (Austria)

  • Are there biomarkers to predict response of ketogenic diet treatment? – Joerg Klepper (Germany)
  • Can the electroclinical phenotype predict the response to KD? Is the improvement of the EEG a predictor to KD response? – Stéphane Auvin (France)
  • What kind of biomarkers can emerge in the future to predict response to KD? – Sabine Scholl-Buergi (Austria)

Developmental outcome of epileptic encephalopathies

Chair: Federico Vigevano (Italy)

  • Introduction – Federico Vigevano (Italy)
  • Pathogenesis of developmental impairment: the role of the gene mutations – Marina Trivisano (Italy)
  • Pathogenesis of developmental impairment: the role of the epileptic activity – Natia Japaridze (Germany)
  • Can we prevent the evolution toward most severe phenotypes? – Sameer Zuberi (United Kingdom)

EEG patterns in genetic epilepsies of childhood and adolescence

Chair: Carlo Alberto Tassinari (Italy)

  • KCNA2 epileptic encephalopathy – Guido Rubboli (Denmark)
  • KCNT1 epilepsy of infancy with migrating focal seizures – Monika Eisermann (France)
  • Unverricht-Lundborg disease – Roberto Michelucci (Italy)
  • Lafora disease – Jose Serratosa (Spain)
  • SLC2A Genetic Generalized Epilepsy (GGE) – Pasquale Striano (Italy)
  • SLC6A1 Myoclonic Atonic Epilepsy (MAE) – Rikke Møller (Denmark)
  • SCN8A epileptic encephalopathy – Elena Gardella (Denmark)
  • Open to a delegate bringing an EEG recording
  • Open to a delegate bringing an EEG recording

Epilepsy and stroke – can we do better?

Chair: Johan Zelano (Sweden)

  • Introduction and the impact of PSE on stroke outcome – Johan Zelano (Sweden)
  • Choosing the right AED in post-stroke epilepsy – Francesco Brigo (Italy)
  • Epilepsy in the context of overt or occult cerebrovascular disease – Hedley Emsley (United Kingdom)

Epilepsy: care, costs, outcome

Chair: Eugen Trinka (Austria)

  • Costs and socio-economic aspects of epilepsy care – Hajo Hamer (Germany)
  • Transborder epilepsy care – Bogdan Lorber (Slovenia)
  • Life expectancy in people with epilepsy – Claudia Granbichler (Austria)
  • Acute symptomatic seizures: costs and outcomes – Alla Guekht (Russia)

Establishment of epilepsy surgery centres in low resource situations

Chair: David Steven (Canada)

  • Establishment of epilepsy surgery in Peru – David Steven (Canada)
  • Is non-invasive evaluation enough? Experience from a paediatric epilepsy unit in India – Pradnya Gagdil (India)
  • Small steps for big changes: epilepsy surgery in Armenia – Biayna Sukhudyan (Armenia)
  • The difficult way in Eastern Europe: Bulgaria and Romania are overcoming the gap – Petia Dimova (Bulgaria) & Ioana Mindruta (Romania)

European Study on the Burden and Care of Epilepsy (ESBACE)

Chair: Jakob Christensen (Denmark)

  • Prevalence of epilepsy in Europe – Christine Linehan (Ireland)
  • Cost of epilepsy in Europe – Poul Jennum (Denmark)
  • Seizure management in hospitals in Europe – Tony Marson (United Kingdom)
  • Provision of epilepsy care in Europe – Kristina Malmgren (Sweden)

How do we safely stop, start and supervise the use of valproate in women with epilepsy?

Chair: Tony Marson (United Kingdom)

  • New JME diagnosis in a 12 year old or 18 year old female – Helen Cross (United Kingdom)
  • Women with well controlled IGE on valproate planning pregnancy – Tony Marson (United Kingdom)
  • Women with poorly controlled IGE on valproate planning pregnancy – Reetta Kälviäinen (Finland)
  • Women with unplanned pregnancy on valproate – Torbjörn Tomson (Sweden)

How to handle polypharmacy and pharmacokinetic interactions in clinical practice?

Chair: Cecilie Johannessen Landmark (Norway)

  • Interactions between AEDs – Cecilie Johannessen Landmark (Norway)
  • Interactions with other drug classes – Yury Kiselev (Norway)
  • Polypharmacy aspects in the elderly, patient and population aspects – Arton Baftiu (Norway)
  • Handling of pharmacokinetic interactions with therapeutic drug monitoring – Svein Johannessen(Norway)

Imitators of epilepsy

Chair: Iris Unterberger (Austria)

  • Paroxysmal dyskinesias – Iris Unterberger (Austria)
  • Syncopes – Roland Thijs (Netherlands)
  • Sleep-related paroxysmal disorders – Rami Khatami (Switzerland)

Integrating psychological treatments into comprehensive epilepsy care – comparing opportunities, challenges and solutions across countries

Chair: Rosa Michaelis (Germany/Austria)

  • Inpatient psychological support and outpatient psychoeducation in Austria – Andrea Egger-Rainer (Austria)
  • Offering psychological support for individuals with impairments in social cognition in Switzerland – Therese Siegenthaler (Switzerland)
  • Possibilities of supporting self-control in people with epilepsy in Switzerland (case example) – Siegward Elsas (Switzerland)
  • Put off by seizures? The frequency and management of seizures during psychotherapeutic sessions with patients with epilepsy or psychogenic non-epileptic seizures – Markus Reuber (United Kingdom)
  • Mindful care for people with epilepsy – developments in France – Prisca Bauer-Sola (France)
  • Experiences of successful collaborations when integrating psychological treatments in everyday clinical care for those who suffer from epilepsy – Tobias Lundgren (Sweden)

Neonatal status epilepticus: when etiology makes the difference

Chair: Lucia Fusco (Italy)

  • Neonatal status epilepticus in hypoxic-ischemic etiology in preterm and term neonates, choose when treatment is mandatory – Ronit Pressler (United Kingdom)
  • Neonatal status epilepticus in acquired etiologies, when etiology and treatment are straightforward – Lucia Fusco (Italy)
  • Neonatal status epilepticus in metabolic etiology, when tailored therapies can change the prognosis – Monika Eisermann (France)
  • Neonatal status epilepticus in genetic etiology, an opportunity for personalized therapies – Maria Roberta Cilio (USA)

NORSE and FIRES: what to expect behind classification

Chair: Nicola Specchio (Italy)

  • Is NORSE/FIRES based on inflammatory process? – Eleonora Aronica (Netherlands)
  • What the neuroimaging add to the pathophysiology – Stefano Meletti (Italy)
  • Is it recovery feasible after the acute phase? And in which patients? – Gerhard Kluger (Germany)

Pharmacoresistant epilepsy management in resource-limited settings

Chair: Silvio Basic (Croatia) & Emilija Cvetkovska (FYR Macedonia) & Vladimir Donath (Slovakia)

  • Pharmacoresistant epilepsy – epidemiology and differential diagnosis – Ruta Mameniskiene (Lithuania)
  • Treating epilepsy – therapeutic challenge in countries with limited resource – Stanislav Groppa (Moldova)
  • Epilepsy comorbidities – Joanna Jedrzejczak (Poland)
  • Preoperative evaluation in limited settings – Dragoslav Sokic (Serbia)

Prescribing antiepileptic drugs (AEDs) in people with intellectual disability (ID) – current evidence, complexity, challenges, barriers, possible solutions and direction of research

Chair: Rohit Shankar (United Kingdom)

  • Prescribing in people with ID – Do we need to treat them differently? – Francesca Snoeijen-Schouwenaars (Netherlands)
  • Prescribing in people with ID – what about genetics? – Jurgen Schelaas (Netherlands)
  • Prescribing in people with ID – Matching current evidence to clinics – Brendan McLean (United Kingdom)
  • Prescribing in people with ID – what direction should research take? – Results from the Ep-ID Research Register – William Henley (United Kingdom)

Psychogenic non-epileptic seizures: a neurological or a psychiatric problem?

Chair: Ettore Beghi (Italy)

  • The epileptologist’s viewpoint on the mechanisms and management of PNES – Markus Reuber (United Kingdom)
  • The psychiatrist’s viewpoint on the mechanisms and management of PNES – Massimiliano Beghi (Italy)

Refractory and superrefractory Status Epilepticus (RSE & SRSE)

Chair: Eugen Trinka (Austria)

  • Mortality and costs of RSE and SRSE – Adam Strzelczyk (Germany)
  • Multimodal monitoring in SRSE – Raimund Helbok (Austria)
  • Therapeutic options in RSE and SRSE – Felix Rosenow (Germany)
  • Relevance and treatment of (medical) comorbidities – Stephan Rüegg (Switzerland)

Neuropathology of epilepsy – 2018 update

Chair: Ingmar Blümcke (Germany)

  • Revision of ILAE 2011 Neuropathological classification of focal cortical dysplasias – Ingmar Blümcke (Germany)
  • Pathogenesis of focal cortical dysplasias – Harvey Sarnat (Canada)
  • Epileptogenic cortical tumours – Eleanora Aronica (Netherlands)
  • Hippocampal sclerosis – Maria Thom (United Kingdom)

Targeting the brain-gut-microbiota axis for treatment of epilepsy and related comorbidities

Chair: Sanjay Sisodiya (United Kingdom)

  • The bidirectional link between CNS and gut microbiota in epilepsy and other neuropsychiatric disease – Pasquale Striano (Italy)
  • The potential impact of dietary treatment on gut microbiota and epigenetics – Kaja Selmer (Norway)
  • Peristaltic ideas for new therapeutic strategies: insights from animal models – Emilio Russo (Italy)
  • The MINERVA (MIcrobiota-gut-braiN EngineerRd platform to eVAluate intestinal microflora impact on brain functionality) project – Carmen Giordano (Italy)

The complex semiology of “typical” absence seizures and syndromes

Chair: Athanasios Covanis (Greece)

  • Are typical absence seizures really non-motor? – Iris Unterberger (Austria)
  • Typical absence seizures and syndromes in infancy – Federico Vigevano (Italy)
  • Typical absence seizures and syndromes in childhood – Athanasios Covanis (Greece)
  • Typical absence seizures and syndromes in adolescent and adults – Michalis Koutroumanidis (United Kingdom)

The impact of seizure semiology – a kahoot! video semiology quiz

Chair: Morten Ingvar Lossius (Norway)

  • Differential diagnosis based on seizure semiology – Rune Markhus (Norway)
  • Seizure semiology and the new classification of epileptic seizures in adults – Karl Otto Nakken (Norway)
  • Seizure semiology and the new classification of epileptic seizures in children – Dana Craiu (Romania)
  • Seizure semiology and seizure onset zone – Philippe Ryvlin (Switzerland)

The new European regulatory guidelines on AED development: an update and future directions

Chair: Michel Baulac (France) & Jacqueline French (USA) & Manuel Haas (United Kingdom)

  • Revision of the EMA guidelines on AEDs: remaining issues – Manuel Haas (United Kingdom)
  • New outcome measures for AEDs – Jacqueline French (USA)
  • Acute seizure trials revisited – Eugen Trinka (Austria)

Very high frequency oscillations: Where is the horizon and what important is beyond?

Chair: Gregory Worrell (USA)

  • Insights from animal models – Premysl Jiruska (Czech Republic)
  • Interictal very high frequency oscillations – Milan Brázdil (Czech Republic)
  • Ictal very high frequency oscillations – Naotaka Usui (Japan)
  • VHFOs and micro recordings – Gregory Worrell (USA)

Young Epileptologists Forum: Your first epilepsy research project

Chair: Christos Lisgaras (USA)

  • Empowering the next generation of epileptology – ILAE Young Epilepsy Section – Christos Lisgaras (USA)
  • Developing a novel model of epilepsy; reducing KCC2 in the adult mouse hippocampus – Matt Kelley (USA)
  • Sex- and age-specific functions of GABAA receptors through development and in epilepsy – Aristea Galanopoulou (USA)
  • Clinical research on epilepsy: challenges for younger investigators – Marina Alvim (Brazil)
  • Moving forward with interventions in complex childhood epilepsy – Helen Cross (United Kingdom)